Welcome to our dedicated page for I:SPX Oct 2023 Weekly 3100.000 news (Ticker: INFI), a resource for investors and traders seeking the latest updates and insights on I:SPX Oct 2023 Weekly 3100.000 stock.
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing, and delivering best-in-class medicines for the treatment of challenging diseases, with a particular focus on oncology and inflammation. The company harnesses its robust small molecule discovery and development capabilities to address unmet medical needs.
Infinity's research and development programs stem from the integration of a broad spectrum of scientific expertise, including cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. This multidisciplinary approach enables the company to innovate and advance its pipeline of potential therapies effectively.
Strategic Alliances
Infinity Pharmaceuticals has established substantial partnerships with leading pharmaceutical and biotechnology companies. These alliances are crucial in maximizing the potential of Infinity's product pipeline, allowing the company to leverage external expertise and resources in its quest to bring new treatments to market.
Business and Scientific Expertise
The company's team is composed of passionate, committed, and innovative professionals who bring together a wealth of experience in various fields. This collective expertise is pivotal in driving the company's mission forward, from early-stage research to clinical development and commercialization.
Infinity Pharmaceuticals continuously updates its stakeholders and the public with the latest news and developments. Keeping abreast of these updates is essential for anyone interested in the company's progress and its impact on the pharmaceutical landscape.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported positive results from the Phase 2 MARIO-275 trial, showing a significant survival benefit for urothelial cancer patients treated with eganelisib plus nivolumab. Specifically, 45% of patients were alive at the two-year mark compared to 24% on standard treatment. Financial results include a net loss of $12 million for Q2 2022 and a cash balance of $56.6 million, extending the runway into 2024. The company aims to finalize partnerships before initiating new studies. A conference call is scheduled for today at 4:30 PM EDT.
Infinity Pharmaceuticals (NASDAQ: INFI) will host a conference call on August 9, 2022, at 4:30 PM ET to discuss its second quarter 2022 financial results.
The webcast will be available on the company's website for 30 days post-event. Shareholders can access the call using the ID Number 303241 via toll-free number (800) 715-9871 or international line (646) 307-1963.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will present a corporate overview and participate in 1-on-1 meetings at the H.C. Wainwright Global Investment Conference from May 23-25, 2022. The presentation is scheduled for May 24 at 7:00 am EST, featuring CEO Adelene Perkins. Infinity is focused on developing eganelisib, an innovative, oral, immuno-oncology treatment aimed at reprogramming macrophages, with multiple clinical trials underway, including the pivotal MARIO-4 trial expected to begin by the end of 2022.
Infinity Pharmaceuticals (NASDAQ: INFI) reported its Q1 2022 financial results, showing a net loss of $12.4 million, or $0.14 per share, compared to a loss of $11.6 million in Q1 2021. As of March 31, 2022, the company held $67.1 million in cash, down from $80.7 million at year-end 2021. Infinity plans to initiate the MARIO-4 trial for eganelisib in front-line metastatic triple negative breast cancer by year-end 2022 and the MARIO-P clinical program in Q3 2022, expanding its research into various solid tumors.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on May 3rd, 2022, at 4:30 pm ET to discuss its financial results for the first quarter of 2022. The call can be accessed via a webcast that will be available on Infinity's website for 30 days post-event. Infinity is focused on developing eganelisib, an oral immuno-oncology therapeutic, with several pivotal trials expected to initiate, including the MARIO-4 trial in mTNBC and MARIO-3 for advanced cancer.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced the grant of non-statutory stock options to two new employees on April 6, 2022. A total of 60,000 options were granted at an exercise price of $1.09, matching the stock's closing price on that date. The options have a 10-year term and vest over four years. Infinity continues to develop eganelisib, an oral immuno-oncology therapy aimed at tackling immune suppression in cancer, with several clinical studies scheduled, including the MARIO-4 trial.
Infinity Pharmaceuticals (NASDAQ: INFI) reported its full year 2021 results, highlighting the initiation of important trials for eganelisib. The MARIO-4 registration-enabling trial for front-line metastatic triple negative breast cancer (mTNBC) is set to start by the end of 2022, alongside the rolling initiation of MARIO-P for additional solid tumors in Q3 2022. Infinity ended 2021 with approximately $81 million in cash. The net loss for the year was $45.3 million, a slight increase from $40.5 million in 2020. The company expects a 2022 net loss between $45 million and $55 million.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company, will hold a conference call on March 29, 2022, at 4:30 p.m. ET to discuss its financial results for Q4 and full year 2021. The call will be accessible via webcast, which will remain available for 30 days post-event. Infinity is developing eganelisib, a first-in-class oral immuno-oncology therapy, with multiple ongoing clinical studies including pivotal trials for advanced cancer. For more details, visit www.infi.com.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced participation in the 32nd Annual Oppenheimer Healthcare Conference on March 16, 2022, from 2:40 PM to 3:10 PM ET. CEO Adelene Perkins will present an overview and engage in 1-on-1 meetings. The company is developing eganelisib, an innovative oral immuno-oncology therapeutic, currently in multiple clinical studies including MARIO-4, MARIO-3, MARIO-275, and MARIO-P. A replay of the presentation will be accessible for 90 days following the event.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced a virtual fireside chat on January 27 at 10:30 am ET, featuring discussions on eganelisib, an oral immuno-oncology therapy. The event will include Infinity's Executive Leadership Team and is hosted by B. Riley biotech analyst Kalpit Patel.
Infinity is focused on advancing eganelisib through clinical trials, including the pivotal MARIO-4 trial for mTNBC and ongoing studies in combination therapies across various cancer types.
FAQ
What is the market cap of I:SPX Oct 2023 Weekly 3100.000 (INFI)?
What is the primary focus of Infinity Pharmaceuticals?
What capabilities does Infinity Pharmaceuticals possess?
Who are Infinity Pharmaceuticals' strategic partners?
What is the mission of Infinity Pharmaceuticals?
What makes Infinity Pharmaceuticals unique?
What areas of expertise does the Infinity team bring together?
How does Infinity Pharmaceuticals contribute to the pharmaceutical field?
Where can I get the latest updates about Infinity Pharmaceuticals?
What types of diseases is Infinity Pharmaceuticals targeting?
Why are strategic alliances important for Infinity Pharmaceuticals?
